Holger Neecke - MolMed S Insider

MolMed S p A -- Germany Stock  

EUR 0.41  0.01  2.38%

Director Business Development & Investor Relations

Dr. Holger Neecke Ph.D. serves as Director of Business Development Investor Relations at Molecular Medicine S.p.A. He joined the Company in October 2001. Before that he worked at Biopolo Scrl where he developed and evaluated business plans for startup companies. At the Company he has acquired experience in biotech business development particularly by structuring negotiating and finalizing license agreements with pharmacy and biotech companies and institutions in Europe Japan and the United States. He gained a degree in Molecular Biology from Universitaet Basel a Masters of Business Administration from Universita Commerciale Luigi Bocconi and a Doctorate in Philosophy in Genetics from Universita degli Studi di Milano.
Age: 43        

Management Efficiency

The company has return on total asset (ROA) of (18.1) % which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (61.21) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.

Similar Executives

Showing few of many executives

DIRECTOR Since

Gangcheng HuangIndustrial and Commercial Bank
2009
Roger CorbettWal Mart Stores Inc
2006
Pamela CraigWal Mart Stores Inc
2013
Suzanne JohnsonPfizer Inc
2007
James SmithPfizer Inc
2014
Rongrong GeIndustrial and Commercial Bank
2012
Joseph EchevarriaPfizer Inc
2015
Jianian ZhongIndustrial and Commercial Bank
2009
Shaoxin YangIndustrial and Commercial Bank
2016
Steven ReinemundWal Mart Stores Inc
2010
Robson WaltonWal Mart Stores Inc
2015
Timothy FlynnWal Mart Stores Inc
2012
Thomas HortonWal Mart Stores Inc
2014
James KiltsPfizer Inc
2007
Zhoulin FeiIndustrial and Commercial Bank
2015
Xiaoya WangIndustrial and Commercial Bank
2012
Linda WolfWal Mart Stores Inc
2005
Fengchao ChengIndustrial and Commercial Bank
2015
Shantanu NarayenPfizer Inc
2013
Dennis AusielloPfizer Inc
2015
Fuqing ZhengIndustrial and Commercial Bank
2015

Entity Summary

MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. and employs 23 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add MolMed S p A to your portfolio

Top Management

MolMed S p Leadership Team
Gian Rizzardi, Director, Ph.D
Marina Bue, Director
Didier Trono, Director
Silvia Pisante, Executive
Mario Masciocchi, Director
Carlo Incerti, Director
Raffaella Ruggiero, Director
Holger Neecke, Director
Luca Alberici, Executive
Maurizio Tassi, Director
Daniele Pieraccioli, Director, Ph.D
Alberto Carletti, Director
Laura Ferro, Director
Marco Dieci, Director, Ph.D
Catia Traversari, Director, Ph.D
Lorenzo Salieri, Director
Elizabeth Robinson, Director
Riccardo Palmisano, CEO
Sabina Grossi, Director, Ph.D
Alfredo Messina, Director
Monica Masolo, Director
Germano Carganico, Executive, Ph.D
Claudio Bordignon, Chairman, Ph.D
Gianluigi Fiorendi, Director
Andrea Quaglino, Director
Khalid Islam, Director, Ph.D
Laura Villa, Director
Cynthia Giuliani, Director
Antonio Lambiase, Director, Ph.D
Marco Manoni, Director
Tiziano Andreoli, Director

Stock Performance

MolMed S Performance Indicators
Return On Equity(61.21) %
Return On Asset(18.1) %
Current Valuation195.6 M
Price to Earning(13.82) times
Price to Book11.53 times
Price to Sales9.28 times
Revenue22.42 M
Gross Profit1000 K
EBITDA(10.6 M)
Net Income(12.02 M)